Integris Medtech IPO Description – Integris Medtech is a diversified global MedTech platform operating across cardiovascular devices and laboratory solutions. It is the second-largest Indian-headquartered diversified medical technology company by operating revenue in FY25 (Source: F&S Report).
Integris Medtech’s portfolio spans over 22,000 SKUs across more than 200 global brands, serving over 9,500 laboratories and 2,000+ hospitals and cathlabs worldwide as of 30 June 2025. The laboratory solutions segment includes clinical diagnostics and scientific laboratory solutions, generating INR 1,241.25 crore in revenue in FY25. Clinical diagnostics contributed 54.87% of lab solutions revenue in FY25, reflecting a shift toward higher-value diagnostic offerings.
The cardiovascular portfolio covers the full interventional pathway—from vascular access and lesion preparation to coronary therapy. The company is India’s second-largest coronary stent manufacturer by volume, with ~22% share in drug-eluting stents, and among the few Indian players manufacturing all three classes of medical devices. As of 30 June 2026, Integris employs1,879 staff.
Promoters of Integris Medtech – Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh and Punita Sharma
Integris Medtech IPO Details
| Integris Medtech IPO Dates | Coming soon |
| Integris Medtech Issue Price | Coming soon |
| Fresh Issue | INR 925.00 crore |
| Offer For Sale | 2,16,74,531 shares |
| Total IPO Size | 2,16,74,531 shares |
| Minimum Bid (Lot Size) | Coming soon |
| Pre-issue Shares | *** shares |
| Face Value | INR 1 per share |
| Listing On | NSE, BSE |
Integris Medtech IPO Allocation in Different Categories
Integris Medtech Financial Performance
| FY 2023 | FY 2024 | FY 2025* | Q1 FY 2026* | |
| Revenue | 1,348.10 | 1,553.38 | 2,332.81 | 606.50 |
| Expenses | 1,316.39 | 1,536.93 | 2,227.02 | 581.38 |
| Net Income | (40.54) | (4.88) | 67.70 | 30.12 |
| Margin (%) | (3.01) | (0.31) | 2.90 | 4.97 |
Proforma financial data
Integris Medtech Offer News
Integris Medtech Valuations & Margins
| FY 2023 | FY 2024 | FY 2025* (Pre-Issue) | FY 2026** (Post-Issue) | |
| EPS | -5.99 | -1.38 | 4.93 | – |
| PE Ratio | – | – | – | – |
| Price/Sales Ratio | – | – | – | – |
| Price/Book Ratio | – | – | – | – |
| Current Ratio | – | – | – | – |
*Proforma financial data
| FY 2023 | FY 2024 | FY 2025 | |
| RONW (%) | (1.85) | (0.44) | 1.84 |
| NAV | 323.91 | 313.11 | 316.09 |
| ROCE (%) | 9.41 | 8.33 | 14.51 |
| EBITDA (%) | 12.52 | 12.26 | 16.26 |
| Debt/Equity | 0.19 | 0.27 | 0.50 |
Evaluate the quality of an IPO using these essential investing ratios to make an informed decision.
Integris Medtech IPO Anchor Investors
Integris Medtech raises () from anchor investors. Integris Medtech Anchor bid date is ().
| Bid Date | Coming soon |
| Shares Offered | Coming soon |
| Anchor Portion (INR Cr.) | Coming soon |
| Anchor lock-in period end date for 50% shares (30 Days) | Coming soon |
| Anchor lock-in period end date for remaining shares (90 Days) | Coming soon |
Integris Medtech IPO GMP Today (Daily Trend)
Integris Medtech Offer Objectives
The company proposes to utilize net proceeds from the issue towards the following objects:
- Repayment/prepayment, in full or part, of certain borrowings availed of by the company – INR 59 crore
- Funding of working capital requirements of the company – INR 115 crore
- General Corporate Purposes
Integris Medtech IPO Subscription – Live Updates
Coming soon
() shares allotted to anchor investors are not included in these calculations.
Integris Medtech – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Integris Medtech | – | 4.93 | 1.84 | 316.09 | 1,902.47 |
| Poly Medicure | 56.02 | 34.13 | 12.26 | 278.46 | 1,669.83 |
| Laxmi Dental | 53.95 | 6.07 | 16.09 | 37.71 | 239.11 |
Integris Medtech IPO Allotment Status
You can check Integris Medtech IPO allotment status on KFin Technologies Limited website. Click on this link to get the allotment status. Often not getting IPO allotment? Learn how to improve your IPO allotment chances.
Integris Medtech IPO Dates & Listing Performance
| IPO Opening Date | Coming soon |
| IPO Closing Date | Coming soon |
| Finalization of Basis of Allotment | Coming soon |
| Initiation of refunds | Coming soon |
| Transfer of shares to demat accounts | Coming soon |
| Integris Medtech IPO Listing Date | Coming soon |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Integris Medtech IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Investmentz –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
SBI Securities –
Samco Securities –
SMC Global –
Swastika Investmart –
Ventura Securities –
Integris Medtech IPO Lead Manager
ICICI SECURITIES LIMITED
ICICI Venture House, Appasaheb Marathe Marg
Prabhadevi, Mumbai 400 025, Maharashtra, India
Tel: +91 22 6807 7100
E-mail: [email protected]
Website: www.icicisecurities.com
Integris Medtech Offer Registrar
KFIN TECHNOLOGIES LIMITED
Selenium Tower – B, Plot 31 & 32, Gachibowli,
Financial District, Nanakramguda, Serilingampally,
Hyderabad – 500 032
Tel: +91 40 6716 2222
E-mail: [email protected]
Website: www.kfintech.com
INTEGRIS MEDTECH LIMITED
Unit 702 & 703, BPTP Capital City,
Sector 94, Noida 201 301,
Uttar Pradesh, India
Phone: +91 120 4531422
Email: [email protected]
Website: www.integrismedtech.com
IPO Resources
How many shares in Integris Medtech IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 75%, NII – 15%, and Retail – 10%.
How to apply in Integris Medtech Public Offer?
What is Integris Medtech IPO GMP today?
Integris Medtech IPO GMP today is INR NA per share.
What is Integris Medtech kostak rate today?
Integris Medtech kostak rate today is INR NA per application.
What is Integris Medtech Subject to Sauda rate today?
Integris Medtech Subject to Sauda rate today is INR NA per application.
Krishna comes from a family of investors and financial analysts, She learnt wading through regulatory filings pretty early in her career. She has several years of experience in financial and industry analysis under her belt. At IPO Central, Krishna plays twin roles of Contributor and Head of research desk.
